The COVID-19 Pandemic in a Hispanic Population: A Primary Care Perspective

References

1. ↵
   1. Li Q,
   2. Guan X,
   3. Wu P,
   4. et al

   . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382:1199–1207.

   OpenUrlCrossRefPubMed
2. ↵
   1. Skegg D,
   2. Gluckman P,
   3. Boulton G,
   4. et al

   . Future scenarios for the COVID-19 pandemic. The Lancet 2021;397:777–78.

   OpenUrl
3. ↵
   1. He W,
   2. Zhang ZJ,
   3. Li W

   . Information technology solutions, challenges, and suggestions for tackling the COVID-19 pandemic. Int J Inf Manage 2021;57:102287.

   OpenUrlCrossRefPubMed
4. ↵
   1. Mueller JT,
   2. McConnell K,
   3. Burow PB,
   4. Pofahl K,
   5. Merdjanoff AA,
   6. Farrell J

   . Impacts of the COVID-19 pandemic on rural America. Proc Natl Acad Sci USA 2021;118.
5. ↵
   1. Ravens-Sieberer U,
   2. Kaman A,
   3. Erhart M,
   4. Devine J,
   5. Schlack R,
   6. Otto C

   . Impact of the COVID-19 pandemic on quality of life and mental health in children and adolescents in Germany. European child & adolescent psychiatry 2021;1–11.
6. ↵
   1. Lin S,
   2. Sattler A,
   3. Smith M

   . Retooling primary care in the COVID-19 era. Paper presented at the Mayo Clinic Proc 2020;95:1831–34.

   OpenUrl
7. ↵
   1. Greenhalgh T,
   2. Knight M,
   3. Buxton M,
   4. Husain L

   . Management of post-acute covid-19 in primary care. BMJ, 2020;370.
8. ↵
   1. Sisó-Almirall A,
   2. Brito-Zerón P,
   3. Conangla Ferrín L

   , on behalf of the CAMFiC long COVID-19 Study Groupet al. Long COVID-19: Proposed primary care clinical guidelines for diagnosis and disease management. IJERPH 2021;18:4350.

   OpenUrl
9. ↵
   1. Blecker S,
   2. Jones SA,
   3. Petrilli CM,
   4. et al

   . Hospitalizations for chronic disease and acute conditions in the time of COVID-19. JAMA Intern Med 2021;181:269–71.

   OpenUrl
10. ↵
    1. Vaughan L,
    2. Veruttipong D,
    3. Shaw JG,
    4. Levy N,
    5. Edwards L,
    6. Winget M

    . Relationship of socio-demographics, comorbidities, symptoms and healthcare access with early COVID-19 presentation and disease severity. BMC Infect Dis 2021;21:40.

    OpenUrl
11. ↵
    1. Rawaf S,
    2. Allen LN,
    3. Stigler FL

    , Global Forum on Universal Health Coverage and Primary Health Careet al. Lessons on the COVID-19 pandemic, for and by primary care professionals worldwide. Eur J Gen Pract 2020;26:129–33.

    OpenUrlPubMed
12. ↵
    1. Berger Z,
    2. Altiery DE,
    3. Jesus V,
    4. Assoumou SA,
    5. Greenhalgh T

    . Long COVID and Health Inequities: The Role of Primary Care. Milbank Q. 2021;99:519–41.

    OpenUrlCrossRefPubMed
13. ↵
    1. Harnden A,
    2. Lim WS,
    3. Earnshaw A

    . COVID-19 vaccination programme: a central role for primary care. Br J Gen Pract. 2021;71:52–53.

    OpenUrlFREE Full Text
14. ↵
    1. Alobuia WM,
    2. Dalva-Baird NP,
    3. Forrester JD,
    4. Bendavid E,
    5. Bhattacharya J,
    6. Kebebew E

    . Racial disparities in knowledge, attitudes and practices related to COVID-19 in the USA. J Public Health (Oxf) 2020;42:470–78.

    OpenUrlCrossRefPubMed
15. ↵
    1. Baquero B,
    2. Gonzalez C,
    3. Ramirez M,
    4. Chavez Santos E,
    5. Ornelas IJ

    . Understanding and Addressing Latinx COVID-19 Disparities in Washington State. Health Educ Behav 2020;47:845–49.

    OpenUrl
16. ↵
    US Centers for Disease Control and Prevention, R. f. C.-i., Hospitalization, and Death by Race/Ethnicity, (last accessed July 2021). Available at: https://www.cdc.gov/coronovirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html.
17. ↵
    1. Macias Gil R,
    2. Marcelin JR,
    3. Zuniga-Blanco B,
    4. Marquez C,
    5. Mathew T,
    6. Piggott DA

    . COVID-19 pandemic: disparate health impact on the Hispanic/Latinx population in the United States. J Infect Dis 2020;222:1592–5.

    OpenUrlPubMed
18. ↵
    FDA. (2021). In Vitro Diagnostics EUAs - Serology and Other Adaptive Immune Response Tests for SARS-CoV-2. Retrieved from https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2.
19. ↵
    1. Haddad F,
    2. Lamb CC,
    3. Kullar R,
    4. Sakoulas G

    . Point-Of-Care Clinical Evaluation of the Clungene® SARS-CoV-2 Virus IgG/IgM 15-minute rapid test cassette with the Cobas® Roche RT-PCR platform in patients with or without Covid-19. LymphoSign Journal 2021;8:55–63.

    OpenUrl
20. ↵
    1. Lamb CC,
    2. Haddad F,
    3. Lopez-Yunez A,
    4. Carroll M,
    5. Moncrieffe J

    . Expanded clinical evaluation of the CLUNGENE Rapid Covid-19 Antibody Test. Journal of Clinical and Cellular Immunology 2021;12.
21. ↵
    1. Haddad F

    . (2020, 7/27/2020). IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04402814?cond=clungene&draw=2&rank=1.
22. ↵
    1. Lamb C

    . COVID-19 diagnostic testing: Lessons learned for innovative product development during a public health emergency. JCB. 2020;25.
23. ↵
    1. Ragnesola B,
    2. Jin D,
    3. Lamb CC,
    4. Shaz BH,
    5. Hillyer CD,
    6. Luchsinger LL

    . COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors. BMC Res Notes 2020;13:1–7.

    OpenUrlCrossRef
24. ↵
    1. Osher G,
    2. Lamb CC,
    3. Ibarra Y,
    4. Erickson-Samson D

    . Observational Study of SARS-CoV-2 Antibody Immune Response in a Cohort of Patients at a North Suburban Chicago, Illinois Physician's. Practice. LymphoSign Journal 2020;7:104–8.

    OpenUrl
25. ↵
    FDA. (2020). Clungene SARS-COV-2 VIRUS (COVID-19) IgG/IgM Rapid Test Cassette. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm?lid=660403&lpcd=QKO.
26. ↵
    CLUNGENE. (2020). CLUNGENE COVID-19 IgG/IgM Rapid Test Kit EUA submission # EUA201121.
27. ↵
    1. Lamb C,
    2. Haddad F,
    3. Owens C,
    4. Lopez-Yunez A,
    5. Carroll M,
    6. Moncrieffe J

    . Updated Clinical Evaluation of the CLUNGENE Rapid COVID-19 Antibody Test. Healthcare 2021;9:1124.

    OpenUrl
28. ↵
    1. Dixon BE,
    2. Wools-Kaloustian KK,
    3. Fadel WF,
    4. et al

    . Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study. PLoS One 2021;16:e0241875.

    OpenUrl
29. ↵
    1. Sudre CH,
    2. Lee KA,
    3. Lochlainn MN,
    4. et al

    . Symptom clusters in COVID-19: A potential clinical prediction tool from the COVID Symptom Study app. Sci Adv 2021;7.
30. ↵
    1. Jin X,
    2. Lian J-S,
    3. Hu J-H,
    4. et al

    . Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69:1002–1009.

    OpenUrlAbstract/FREE Full Text
31. ↵
    1. Group RC,
    2. Horby P,
    3. Lim WS,
    4. et al

    . Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med 2020.
32. ↵
    1. Procter BC,
    2. Ross C,
    3. Pickard V,
    4. Smith E,
    5. Hanson C,
    6. McCullough PA

    . Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med 2020;21:611–14.

    OpenUrlCrossRef
33. ↵
    1. Quinn KL,
    2. Bell CM

    . Pandemic health consequences: Grasping the long COVID tail. PLoS Med 2022;19:e1003891.

    OpenUrl
34. ↵
    1. Halpin SJ,
    2. McIvor C,
    3. Whyatt G,
    4. et al

    . Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation. J Med Virol 2021;93:1013–22.

    OpenUrlPubMed
35. ↵
    1. Nalbandian A,
    2. Sehgal K,
    3. Gupta A,
    4. et al

    . Post-acute COVID-19 syndrome. Nat Med 2021;27:601–15.

    OpenUrlCrossRefPubMed
36. ↵
    1. Chen M,
    2. Qin R,
    3. Jiang M,
    4. Yang Z,
    5. Wen W,
    6. Li J

    . Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review. Int J Infect Dis 2021;104:415–22.

    OpenUrlPubMed
37. ↵
    1. Lisboa Bastos M,
    2. Tavaziva G,
    3. Abidi SK,
    4. et al

    . Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ 2020;370:m2516.

    OpenUrlAbstract/FREE Full Text
38. ↵
    1. Kucirka LM,
    2. Lauer SA,
    3. Laeyendecker O,
    4. Boon D,
    5. Lessler J

    . Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med 2020;173:262–67.

    OpenUrlCrossRefPubMed
39. ↵
    1. Bolke E,
    2. Matuschek C,
    3. Fischer JC

    . Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med 2020;383:1694–5.

    OpenUrlCrossRefPubMed
40. ↵
    1. Chavarot N,
    2. Leruez-Ville M,
    3. Scemla A,
    4. et al

    . Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. Kidney Int 2021;99:486–88.

    OpenUrlPubMed